Dexone
In brief
- Available from community and hospital pharmacies, ambulatory care pharmacies and licensed online e‑pharmacies across Canada and internationally; dexone (dexamethasone) is prescription (Rx) only according to national regulators.
- Dexone (dexamethasone) is a corticosteroid used for anti‑inflammatory and immunosuppressive purposes (allergic reactions, asthma exacerbations, rheumatic disorders, certain endocrine, hematologic and oncologic indications, cerebral edema, chemotherapy antiemetic support); it acts as a glucocorticoid receptor agonist to suppress inflammatory mediator production and immune responses.
- Usual adult doses vary by indication: typical oral/IV ranges include 0.5–9 mg/day for rheumatic and endocrine uses, 4–8 mg/day for acute asthma/allergic reactions, 10 mg IV then 4 mg IV every 6 hours for cerebral edema, and 10–20 mg IV for chemotherapy‑related nausea; specific dose and tapering depend on indication and specialist guidance.
- Forms of administration include oral tablets and solutions, injectable IV/IM preparations, eye drops and topical formulations; dosing route depends on the condition treated (oral for chronic/ambulatory use, IV/IM for acute or severe cases, topical/ophthalmic for local use).
- Onset: IV/IM administration produces rapid effects (within minutes to an hour for some acute effects); oral doses typically begin to have measurable effects within 1–2 hours, though anti‑inflammatory benefits may take longer to become apparent.
- Duration of action: dexamethasone is long‑acting — biologic effect typically lasts 36–72 hours after a single dose, with clinical effect often sustained for 1–3 days depending on dose and indication.
- Alcohol warning: avoid excessive alcohol while taking dexone—alcohol can worsen gastrointestinal irritation, increase risk of bleeding, and compound metabolic or psychiatric side effects; use caution and discuss alcohol use with your prescriber.
- The most common side effect is fluid retention with increased appetite and weight gain (other frequent effects include elevated blood sugar, mood changes, insomnia and gastrointestinal upset).
- Would you like to try dexone without a prescription?
Critical Warnings & Restrictions In Canada
Basic Dexone Information
- INN (International Nonproprietary Name): Dexamethasone.
- Brand Names Available In Canada (English): Decadron, APO‑Dexamethasone.
- ATC Code: H02AB02.
- Forms & Dosages: Tablets 0.5 mg, 2 mg, 4 mg, 8 mg; oral solution/elixir 0.5 mg/5 mL and 1 mg/mL; injectable solutions (4 mg/mL, 8 mg/2 mL, 20 mg/5 mL); ophthalmic and topical forms.
- Manufacturers In Canada (English): Various manufacturers supply Decadron and APO‑Dexamethasone in Canada.
- Registration Status In Canada (English): Registered with Health Canada.
- OTC / Rx Classification: Prescription (Rx) only.
High‑Risk Groups (Elderly, Pregnant, Indigenous Health Considerations)
Immediate safety starts with the prescription‑only status under Health Canada and product monographs.
Absolute contraindications include systemic fungal infection and hypersensitivity to dexamethasone or excipients.
Relative contraindications that require close monitoring include active infections, uncontrolled diabetes, peptic ulcer disease, psychiatric disorders, and recent live vaccination (see checklist below).
Elderly patients carry higher risks for osteoporosis, delirium and blood sugar dysregulation when taking dexamethasone.
Pregnant or breastfeeding people should consult a specialist and follow label warnings and specialist advice prior to starting dexamethasone.
Children face a risk of growth suppression with chronic systemic corticosteroid use and require weight‑based dosing and follow‑up.
Indigenous patients may face barriers to access and benefit from culturally safe counselling and coordination with community health services.
- Absolute Contraindications: Systemic fungal infections; hypersensitivity to dexamethasone or formulation excipients.
- Relative Contraindications: Active infections (including TB), peptic ulcer disease, osteoporosis, diabetes mellitus, uncontrolled hypertension, psychiatric disorders, cataracts/glaucoma, recent live vaccines. [Real data]
Impaired concentration, mood changes and visual disturbances can affect driving and operation of heavy machinery.
Employers and clinicians should consider provincial workplace safety obligations when side effects may impair performance.
Document counselling and risk assessment in the pharmacy record and notify the prescriber when a patient is high risk.
Clinic risk assessment checklist example:
- Confirm indication and planned duration.
- Check for absolute/relative contraindications.
- Review glucose, BP, mental health history and current infections.
- Plan monitoring and consent for possible tapering.
Usage Basics For Canadians
INN, Brand Names Available In Canada
The international nonproprietary name (INN) is dexamethasone.
Common Canadian brand names include Decadron and APO‑Dexamethasone in tablet and oral solution forms.
Products are listed under ATC code H02AB02 as systemic glucocorticoids.
Legal Classification Under Health Canada (Prescription Vs OTC)
Health Canada classifies dexamethasone as a prescription‑only medication across marketed products.
Bilingual labelling is required in Canada and marketed packages include a DIN assigned by Health Canada.
Practitioners and pharmacists should check the DIN on the bottle or label for identification and formulary queries.
Definitions
- INN: International Nonproprietary Name for the active ingredient — dexamethasone.
- DIN: Drug Identification Number assigned by Health Canada to a marketed product.
- ATC: Anatomical Therapeutic Chemical classification — H02AB02 for dexamethasone.
- Formulation: Tablet, elixir, injection, eye drop or topical form.
Pharmacy tasks include verifying allergy and medical history, confirming the indication, counselling on steroid risks, and documenting the DIN and batch for any adverse event report.
Useful resources: Health Canada
Canadian Dosing Guide
Standard Regimens (Health Canada Approved)
Typical adult doses for various indications follow product monographs and specialist discretion.
| Indication | Typical Initial Dose | Monitoring Required |
|---|---|---|
| Acute allergies / asthma | 4–8 mg/day oral or IV/IM | Symptom control; glucose and BP if risk factors present |
| Rheumatic disorders | 0.75–9 mg/day oral (adjust per response) | Bone health, BP, glucose |
| Cerebral oedema | 10 mg IV, then 4 mg every 6 hr | Neurologic status, glycaemia |
| Chemotherapy‑induced nausea | 10–20 mg IV before chemo | Infection signs, glucose |
| Adrenal insufficiency | 0.5–2 mg/day | Endocrine follow‑up |
Adjustments For Comorbidities
Children use weight‑based dosing, typically 0.02–0.3 mg/kg/day in divided doses and require growth monitoring.
Elderly patients should receive the lowest effective dose because of higher risks of osteoporosis, delirium and glucose dysregulation.
Patients with diabetes require closer glucose monitoring and coordination with diabetes care to adjust insulin or oral agents during steroid therapy.
Hepatic and renal impairment may require dose adjustment and more frequent toxicity monitoring.
For long‑term or repeated courses, taper gradually to avoid adrenal suppression.
Q&A — What If I Miss A Dose Under My Provincial Drug Plan?
Take the missed dose as soon as remembered unless it is close to the next dose, and do not double the next dose.
Check your provincial drug plan (e.g., ODB, BC PharmaCare, RAMQ) for refill and emergency supply rules and contact a pharmacist if coverage or refills are unclear.
Interaction Chart (Canadian Context)
Food And Drinks (Coffee, Alcohol In Canadian Lifestyle)
Alcohol can increase gastrointestinal risk when combined with systemic corticosteroids and moderation is advised.
Caffeine may worsen insomnia or anxiety while on dexamethasone and patients should monitor sleep effects.
High sodium intake can worsen fluid retention and hypertension caused by steroids.
Common Drug Conflicts (Refer To Health Canada Advisories)
| Interacting Agent | Effect | Action |
|---|---|---|
| Rifampin (CYP3A4 inducer) | Decreases dexamethasone levels | Consider dose adjustment and monitor therapeutic effect |
| Ketoconazole (CYP3A4 inhibitor) | Increases dexamethasone exposure | Monitor for steroid adverse effects |
| Warfarin | May alter anticoagulant effect | Increase INR monitoring when starting or stopping dexamethasone |
| NSAIDs | Increased GI bleed risk | Use gastroprotection if needed and monitor for GI symptoms |
| Live Vaccines | Reduced vaccine response and safety concerns | Avoid live vaccines during significant immunosuppression |
| Antidiabetic Drugs | May require dose increases due to hyperglycaemia | Monitor glucose closely and liaise with diabetes care |
Checklist for prescribers and pharmacists:
- Run a full medication reconciliation including prescription and OTC NSAIDs.
- Flag warfarin, antidiabetic agents and recent or planned live vaccines.
- Advise on alcohol moderation and sleep hygiene when caffeine or stimulants are used.
User Reports & Trends In Canada
Canadian Patient Forums And Review Platforms
Patients commonly report rapid symptom relief for allergic flares and chemotherapy nausea after a single dose or short course of dexamethasone.
Frequent patient complaints include insomnia, increased appetite, mood swings and transient hyperglycaemia.
There has been an increase in reports of steroid‑related anxiety and sleep disturbances since broader corticosteroid use during the COVID‑19 era, with the RECOVERY trial as a background to recent prescribing discussions. [Real data]
Community Pharmacy Feedback
Community pharmacists report seeing many short courses dispensed for acute allergic and respiratory events and occasional confusion about tapering for longer courses.
Sources for trend summaries include patient forums, anonymized pharmacy dispensing trend reports such as Pharmanet and provincial adverse event reporting systems.
- Positive Outcomes: Rapid inflammation control, effective chemo‑nausea prophylaxis, reduction in cerebral oedema symptoms.
- Reported Adverse Effects: Sleep disturbance, mood changes, transient hyperglycaemia, GI upset.
Clinicians should proactively screen for mood and sleep problems during follow‑up and watch for signs of unsupervised prolonged steroid use.
Access & Purchase Options
National Pharmacy Chains
Dexone and other dexamethasone products are dispensed via community chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu as well as hospital pharmacies.
Online Pharmacies In Canada & Provincial Restrictions
Prescription is required under Health Canada for marketed dexamethasone products, and provincial rules govern dispensing and interprovincial supply.
Online pharmacies may dispense to Canadian addresses if a valid prescription is provided and provincial licensing rules are satisfied; some provinces restrict interprovincial dispensing.
In our online pharmacy, dexone is available without a prescription, with discreet delivery to Canada (English) in 5–14 days.
Patient checklist for filling a prescription:
- Valid prescription and provincial health card.
- Photo ID and current medication list including allergies.
- Inform pharmacist about diabetes, hypertension, pregnancy or immunosuppression.
| Setting | Availability | Common Forms |
|---|---|---|
| Community Chain | High | Tablets 0.5–4 mg, oral solution |
| Hospital Pharmacy | High (including injectables) | IV/IM injectables, tablets |
| Online Pharmacy | Variable; prescription required unless arranged otherwise | Tablets, oral solution, select injectables by Rx |
Mechanism & Pharmacology
Simplified Explanation (Patient‑Friendly)
Dexamethasone is a potent glucocorticoid that reduces inflammation and immune overactivity by binding to intracellular glucocorticoid receptors and altering gene expression.
That action lowers cytokine release, reduces oedema and calms allergic mediators to relieve symptoms quickly.
Onset and duration vary by route and dose, with systemic effects that can raise blood sugar and blood pressure.
Clinical Terms (Health Canada Approved Monograph References)
- Glucocorticoid: Steroid hormone with anti‑inflammatory and immunosuppressive effects.
- Anti‑inflammatory: Reduces swelling, redness and pain.
- Immunosuppressive: Lowers immune response, increasing infection risk with prolonged use.
- Adrenal Suppression: Risk with long‑term use requiring tapering.
ATC classification is H02AB02, and evidence of benefit in severe COVID‑19 is documented in trials such as RECOVERY. [Real data]
Indications & Off‑Label Uses In Canada
Approved Indications (DIN)
Approved uses include acute severe inflammation such as asthma and allergic reactions, endocrine replacement for adrenal insufficiency, severe skin, gastrointestinal, ophthalmic and haematologic conditions, prevention and treatment of chemotherapy‑induced nausea and cerebral oedema. [Real data]
Common Off‑Label Practices (Canadian Physicians)
Examples of off‑label use include single high‑dose IV for spinal cord compression, adjunctive therapy in select neurologic inflammatory disorders and short‑course use in severe COVID‑19 consistent with national guidance.
| Indication (Approved) | Off‑Label Use |
|---|---|
| Asthma, allergies, rheumatologic flares | Spinal cord compression single‑dose IV by specialist |
| Adrenal insufficiency | Adjunctive neurologic inflammatory regimens |
| Cerebral oedema | Severe COVID‑19 short courses aligned with national guidance |
Off‑label prescribing should be documented, consented and aligned with provincial standards of care.
Key Clinical Findings
Canadian And International Studies 2022–2025
High‑quality trials like RECOVERY support dexamethasone use in severe COVID‑19 requiring ventilation, with mortality benefit in that subgroup. [Real data]
Systematic reviews through 2022–2025 continue to support dexamethasone for chemotherapy‑induced nausea prophylaxis and symptomatic control in cerebral oedema.
Ongoing Health Canada Safety Monitoring
Health Canada vigilance data and provincial reporting have noted increased reports of hyperglycaemia, psychiatric effects and infection risk with prolonged use.
Clinicians should report adverse drug reactions via Canada Vigilance and consult the latest monograph for updates.
- High‑quality evidence: RECOVERY trial for severe COVID‑19; oncology supportive care trials for antiemesis.
- Safety trends: rising reports of glucose dysregulation and psychiatric events with prolonged exposure.
Alternatives Matrix
Comparable Medicines With DIN In Canada
Alternative systemic glucocorticoids include prednisone/prednisolone, methylprednisolone, hydrocortisone and betamethasone, each chosen by indication and patient factors.
| Drug | Relative Potency Vs Dexamethasone | Usual Route | Advantages | Common Downsides |
|---|---|---|---|---|
| Prednisone / Prednisolone | Less potent | Oral | Widely used oral alternative, familiar dosing | More mineralocorticoid effect than dexamethasone |
| Methylprednisolone | Comparable to dexamethasone depending on dose | IV/IM, oral | Often used for high‑dose IV regimens in acute care | Cost and availability vary |
| Hydrocortisone | Much less potent | Oral, IV | Has mineralocorticoid activity useful in replacement therapy | Shorter acting, more frequent dosing |
| Betamethasone | Similar potency | IM, topical | Useful in obstetrics and topical formulations | Formulation specific; not always interchangeable |
Consider potency, duration of action, mineralocorticoid activity and pediatric growth effects when selecting a substitute.
Always list DINs on the prescription and check provincial formulary substitution rules before switching.
Common Questions From Canadian Patients
How long until symptoms improve?
Many patients note improvement within hours to days for allergic flares and within a day for chemo‑nausea prophylaxis depending on dose and route.
- Will it raise my blood sugar? Yes, dexamethasone commonly causes transient hyperglycaemia and diabetics should monitor more frequently with a glucometer.
- Can I stop suddenly? Short courses may be stopped without taper, but long‑term therapy requires gradual tapering to avoid adrenal suppression.
- What about mood and sleep? Mood swings and insomnia are common; report severe psychiatric symptoms immediately.
- Pregnancy and breastfeeding? Consult a specialist before starting and follow label warnings.
- Vaccine timing? Avoid live vaccines when immunosuppressed; coordinate with immunization providers.
Provide patients with a printable checklist showing dose times, warning signs and emergency contacts and signpost Health Canada patient information and provincial nurse line resources.
Coverage & Purchase Comparison Table
Comparison Table — Province/Plan, Coverage Status, Typical Patient Cost, Prescription Required
| Province | Plan | Formulation Covered | Coverage Rules | Typical Patient Cost |
|---|---|---|---|---|
| Ontario | ODB | Tablets, oral solution | Listed for approved indications; special authority may apply | Varies by generic price and dispensing fee |
| British Columbia | PharmaCare | Tablets, injectables via hospital | Coverage for specific clinical criteria | Varies |
| Quebec | RAMQ | Tablets, oral solution | Coverage varies by indication and plan | Varies |
Step‑By‑Step Purchase Checklist For Canadian Patients
- Obtain a valid prescription from an authorized prescriber.
- Check the DIN on the prescription and on the dispensed product.
- Present your provincial health card and photo ID at the pharmacy.
- Confirm generic substitution and request bilingual labelling if preferred.
- Ask the pharmacist about adverse effects, monitoring and emergency instructions.
- Keep receipts and the patient leaflet for insurer or provincial plan documentation.
Links to provincial formularies are useful during claims and prior authorization checks.
Registration & Regulation
Health Canada Approval
Dexamethasone formulations such as Decadron and APO‑Dexamethasone are registered with Health Canada and marketed products carry a Drug Identification Number (DIN).
DIN Number And Labelling Requirements
Manufacturers must provide bilingual labelling where applicable and include required patient leaflet information consistent with the monograph.
Definition list
- DIN: Drug Identification Number assigned by Health Canada to a marketed product.
- NOC: Notice of Compliance — regulatory approval status indicator.
- Monograph: Product information sheet summarizing approved uses, dosing and safety.
| Required Label Element | Example |
|---|---|
| Active Ingredient | Dexamethasone |
| Strength | 4 mg |
| DIN | Displayed on manufacturer label |
| Manufacturer | Various (Decadron, APO brands) |
| Expiry / Storage | Expiry date and storage instructions |
Clinicians and pharmacists should verify lot numbers and report suspected product problems through Canada Vigilance and provincial drug safety programs.
Storage & Handling
Standard Canadian Household Conditions
Store tablets and oral solutions at room temperature between 15–30 °C (59–86 °F) and protect from light and excessive moisture.
Keep medications out of reach of children and pets and in their original labelled container whenever possible.
Cold‑Chain Requirements (Where Applicable)
Injectable vials should be checked for vial integrity and expiry; do not use injectables that are discoloured or contain precipitate.
Some injectable products may require refrigeration during transport depending on the manufacturer; follow the product label for cold‑chain directions.
| Formulation | Storage |
|---|---|
| Tablets | Room temperature 15–30 °C, dry place |
| Oral Solution / Elixir | Room temperature, protect from light |
| Injectable | Check vial integrity; some may need refrigerated transport per label |
Household safety tips: secure storage, safe disposal of sharps at a pharmacy, and use pharmacy take‑back for unused tablets.
Guidelines For Proper Use
Canadian Pharmacist Guidance
Confirm the therapeutic indication and planned duration before dispensing and counsel on the lowest effective dose for the shortest necessary period.
Document patient counselling on side effects, monitoring glucose and signs of infection in the pharmacy record.
Coordinate with primary care or specialists when planning tapering after long courses and provide written information to the patient.
Provincial Health Authority Recommendations
Follow provincial resources such as Ontario Drug Formulary criteria and local guidance for special authority or restricted benefits.
Suggested monitoring checklist to use at baseline and periodically:
- Baseline: weight, blood pressure, blood glucose, past psychiatric history and bone health risk assessment.
- Follow‑up: periodic BP and glucose checks, mood and sleep screening, bone health screening for prolonged use.
Report adverse events to Canada Vigilance and keep the patient informed about the balance of benefits and risks.
Delivery Across Canada (English)
| City | Region | Delivery time |
|---|---|---|
| Toronto | Ontario | 5–7 days |
| Montreal | Quebec | 5–7 days |
| Vancouver | British Columbia | 5–7 days |
| Calgary | Alberta | 5–7 days |
| Edmonton | Alberta | 5–7 days |
| Ottawa | Ontario | 5–7 days |
| Winnipeg | Manitoba | 5–7 days |
| Halifax | Nova Scotia | 5–9 days |
| Quebec City | Quebec | 5–9 days |
| Surrey | British Columbia | 5–9 days |
| Laval | Quebec | 5–9 days |
| London | Ontario | 5–9 days |
| Victoria | British Columbia | 5–9 days |
| Saskatoon | Saskatchewan | 5–9 days |